Opinion

Video

Discussing ADC Risks, Benefits, and Regimens With Patients

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how health care professionals use clear, tailored communication to explain antibody-drug conjugate (ADC) risks, benefits, and regimens. They provide education, address concerns, and ensure adherence through counseling and shared decision-making.

Video content above has been prompted by the following:

  • At your institution, how do you effectively communicate with patients about ADC therapies (eg, risks, benefits, treatment regimens)?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Computer Screen in Hospital Radiology Room: Woman Standing Undergoing Mammography Screening Procedure. Screen Showing the Mammogram Scans of Dense Breast Tissues - Image credit: Gorodenkoff | stock.adobe.com
September 3rd 2025

Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
September 3rd 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
In the hospital, the patient undergoes a screening procedure for a mammogram, which is performed by a mammogram. A modern technologically advanced clinic with professional doctors. Image Credit: Valerii Apetroaiei | stock.adobe.com
September 3rd 2025

Suppression of JNK Pathway Drives Resistance to Endocrine and CDK4/6 Therapy in ER-Positive Breast Cancer

Danielle Valletti, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
September 3rd 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes
September 3rd 2025

Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes

Benjamin Gibson, PharmD, PAHM
Vials and flasks in lush green foliage and chemical compounds background, science and medicine, natural remedies... | Image Credit: Nikolai | stock.adobe.com
September 3rd 2025

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Danielle Valletti, Assistant Editor
© 2025 MJH Life Sciences

All rights reserved.